TP53 MUTATIONS NEGATIVELY IMPACT SURVIVAL OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH STANDARD DOSES OF HYPOMETHYLATING AGENTS
EHA Learning Center, Pierre Bories, 214720
CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND T(8;16)(P11;P13): RESULTS FROM AN INTERNATIONAL COLLABORATION
EHA Learning Center, Sabine Kayser, 214721
A PHASE 1 DOSE ESCALATION STUDY OF THE IDH1M INHIBITOR, FT-2102, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
EHA Learning Center, Maria Baer, 214722
RISK FACTORS IN RELAPSE/REFRACTORY AML TREATED WITH DECITABINE
EHA Learning Center, Adolfo De La Fuente, 214723
SAFETY AND PHARMACOKINETICS OF A NOVEL ORAL CAPSULE FORMULATION OF ARSENIC TRIOXIDE, ORH-2014, IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS
EHA Learning Center, Farhad Ravandi-Kashani, 214724
OUTCOMES BY NUMBER OF INDUCTION CYCLES WITH CPX-351 VERSUS 7+3 CHEMOTHERAPY IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (SAML)
EHA Learning Center, Jorge Cortes, 214725
POST HOC EXPLORATORY ANALYSIS OF TWO PHASE 2 TRIALS OF QUIZARTINIB MONOTHERAPY IN PATIENTS WITH FLT3-ITD MUTATED RELAPSED/REFRACTORY AML AND PRIOR FLT3 TYROSINE KINASE INHIBITOR TREATMENT
EHA Learning Center, Jorge Cortes, 214726
RISK FACTORS OF EARLY DEATH FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA UNDER THE TREATMENT OF ATRA, ATO WITH OR WITHOUT CHEMOTHERAPY
EHA Learning Center, LI CHEN, 214728
PHASE II STUDY INCORPORATING A NOVEL BH3-PROFILING BIOMARKER APPROACH OF ALVOCIDIB FOLLOWED BY CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Joshua F. Zeidner, 214729
OUTCOME OF A REAL-LIFE POPULATION OF ACUTE PROMYELOCYTIC LEUKEMIA TREATED ACCORDING TO PETHEMA LPA 2005 PROTOCOL: THE POLISH ADULT LEUKEMIA GROUP (PALG) EXPERIENCE.
EHA Learning Center, Marta Sobas, 214730
GLASDEGIB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) WHO ACHIEVED COMPLETE REMISSION (CR) AND THOSE WHO DID NOT ACHIEVE CR
EHA Learning Center, Jorge Cortes, 214731
HIGH COMPLETE REMISSION RATES WITH ORAL SYK INHIBITOR ENTOSPLETINIB (GS-9973) IN ACUTE MYELOID LEUKEMIA PATIENTS ASSOCIATED WITH HIGH HOXA9/MEIS1 EXPRESSION.
EHA Learning Center, Veerendra Munugalavadla, 214732
WEEKEND VERSUS WEEKDAY DIAGNOSIS AND EARLY MORTALITY IN ACUTE PROMYELOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS IN THE NETHERLANDS
EHA Learning Center, Avinash Dinmohamed, 214733
DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE REAL LIFE EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
EHA Learning Center, Carla Fili, 214734
PROGNOSTIC IMPACT OF SKELETAL MUSCLE ASSESSED BY COMPUTED TOMOGRAPHY SCAN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Nobuhiko Nakamura, 214735
INCIDENCE OF MARROW NEOPLASMS IN BREAST CANCER SURVIVORS: A NATIONAL POPULATION-BASED COHORT STUDY
EHA Learning Center, Norbert Vey, 214736
WILMS TUMOR 1 EXPRESSION IN ACUTE MYELOID LEUKEMIA CORRELATES WITH CYTOGENETICS OR COLLABORATIVE MUTATIONS: HOKKAIDO LEUKEMIA NET STUDY
EHA Learning Center, Daisuke Hidaka, 214737
OUTCOMES FOR T(9;11) PATIENTS ARE NO BETTER THAN FOR OTHER REARRANGEMENT PARTNERS IN 11Q23-REARRANGED ADULT AML: A COMPREHENSIVE REVIEW OF MLL-R AML TREATED AT MEMORIAL SLOAN KETTERING CANCER CENTER
EHA Learning Center, Kamal Menghrajani, 214738
HYPOMETILATING AGENTS (HMA) AS SALVAGE THERAPY IN RELAPSED OR REFRACTORY AML: AN ITALIAN 9-CENTER RETROSPECTIVE STUDY
EHA Learning Center, Marica Laurino, 214739
COMPREHENSIVE ANALYSIS OF THE CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA WITH KOREAN AML REGISTRY
EHA Learning Center, Ho-Jin Shin, 214740
REAL WORLD EVIDENCE ON THE BURDEN OF ILLNESS EXPERIENCED BY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SYSTEMIC MYCOSES
EHA Learning Center, Anna Forsythe, 214741
EVALUATION OF FOOD EFFECT ON PHARMACOKINETICS OF IVOSIDENIB (AG-120), AN ORAL, POTENT, TARGETED, SMALL MOLECULE INHIBITOR OF MUTANT IDH1, IN HEALTHY SUBJECTS
EHA Learning Center, Bin Fan, 214742
AZACITIDINE FRONTLINE AND SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS. CLINICAL EXPERIENCE AND DEVELOPMENT OF RISK SCORE
EHA Learning Center, Silvia Imbergamo, 214743
MYELOID SARCOMAS IN AML TRANSLOCATION (8;21) IS IT STILL A FAVOURABLE RISK GROUP?
EHA Learning Center, Rohan halder, 214744
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: DURABILITY OF RESPONSE IN ZUMA-1
EHA Learning Center, Olalekan O. Oluwole, 214745
THE NOVEL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES GOOD TOLERABILITY AND CLINICAL RESPONSE IN A PHASE 2A STUDY IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
EHA Learning Center, Steven Horwitz, 214746
THE COMBINATION OF IBRUTINIB, LENALIDOMIDE, AND RITUXIMAB (IR2) IS ACTIVE IN RELAPSED/REFRACTORY (R/R) NON−GERMINAL CENTER-LIKE (NON-GCB) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): INTERIM ANALYSIS
EHA Learning Center, Radhakrishnan Ramchandren, 214747
QUALITY OF LIFE IN CUTANEOUS T-CELL LYMPHOMA SUBJECTS TREATED WITH THE ANTI-CCR4 MONOCLONAL ANTIBODY MOGAMULIZUMAB VERSUS VORINOSTAT: RESULTS FROM THE PHASE 3 MAVORIC TRIAL
EHA Learning Center, Pietro Quaglino, 214748
ANALYSIS OF CNS RELAPSES RISK FACTORS IN A POPULATION OF 1615 UPFRONT DLBCL PATIENTS TREATED IN LYSA PROTOCOLS LNH03 AND LNH07-3B
EHA Learning Center, Sophie BERNARD, 214749
SUBSTITUTION OF CISPLATIN FOR CARBOPLATIN OR OXALIPLATIN IN THE DHAP REGIMEN IS ASSOCIATED WITH IMPROVED SURVIVAL IN RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
EHA Learning Center, Eloit Martin, 214750
VCAP-AMP-VECP VERSUS CHOP AS FIRST-LINE CHEMOTHERAPY FOR AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A PROPENSITY SCORE ANALYSIS
EHA Learning Center, Shigeo Fuji, 214751
POSSIBLE FACTORS ON EFFICACY AND SAFETY OF CAR–T THERAPY IN RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA
EHA Learning Center, Haiwen Huang, 214752
TITLE: LENALIDOMIDE PLUS R-CHOP THERAPY PROVIDES DURABLE LONG-TERM REMISSIONS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMBINED ANALYSIS FROM TWO PHASE 2 TRIALS.
EHA Learning Center, Annalisa Chiappella, 214753
FRONT-LINE TREATMENT OF DLBCL WITH 6 VERSUS 8 CYCLES OF R-CHOP IS NOT ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY PATIENTS: RESULTS FROM A RETROSPECTIVE ANALYSIS OF THE SEER-MEDICARE DATABASE
EHA Learning Center, Aijing Shang, 214754
MONITORING OF RHOA G17V MUTATION DURING THE COURSE OF THERAPY IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA BY QUANTITATIVE ALLELE-SPECIFIC PCR WITH LNA-MODIFIED PRIMERS
EHA Learning Center, Yulia Sidorova, 214755
CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOME OF ELDERLY SYSTEMIC T/NK CELL LYMPHOMA IN A RESOURCE-LIMITED COUNTRY: THE RESULT OF THAILAND NATIONWIDE LYMPHOMA REGISTRY
EHA Learning Center, Kitsada Wudhikarn, 214756
RETROSPECTIVE ANALYSIS OF PATIENTS WITH PRIMARY CENTRAL NERVOUS LYMPHOMAS TREATED WITH METHOTREXATE-BASED REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT AND TEMOZOLOMIDE MAINTENANCE
EHA Learning Center, Maria Ljungqvist, 214757
RITUXIMAB, GEMCITABINE AND OXALIPLATIN (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS NOT CANDIDATES FOR HIGH-DOSE THERAPY WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). A SINGLE CENTER STUDY OF 115 PATIENTS
EHA Learning Center, Clarisse Cazelles, 214758
THE HIGH EXPRESSION OF CD38 IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Kaoru Sueoka, 214759
PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) UNDER RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY (RT)
EHA Learning Center, Theodoros Vassilakopoulos, 214761
SOLUBLE INTERLEUKIN-2 RECEPTOR AS A SURROGATE BIOMARKER OF METABOLIC TUMOR VOLUME MEASURED BY 18F-FDG PET/CT IN DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Hajime Senjo, 214762
TAK-659 PLUS BENDAMUSTINE (+/-RITUXIMAB), GEMCITABINE, LENALIDOMIDE, OR IBRUTINIB IN PATIENTS (PTS) WITH ADVANCED NON-HODGKIN LYMPHOMA (NHL)
EHA Learning Center, Sarit Assouline, 214763
82RB PET FOR EARLY DETECTION OF DOXORUBICIN-INDUCED CARDIOTOXICITY
EHA Learning Center, Adam Høgsbro Laursen, 214764
IMPACT OF OMISSION/REDUCTION OF VINCRISTINE FROM R-CHOP THERAPY IN TREATMENT OF GCB TYPE DLBCL
EHA Learning Center, Shoko Marshall, 214765
EPIDEMIOLOGY AND TREATMENT PATTERNS IN LATIN AMERICAN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: FINDINGS FROM THE HEMATO-ONCOLOGY IN LATIN AMERICA (HOLA) OBSERVATIONAL REGISTRY STUDY
EHA Learning Center, Miguel Pavlovsky, 214766
CLINICAL RESPONSE AND PHARMACOKINETICS OF BENDAMUSTINE AS A COMPONENT OF SALVAGE R-B(O)AD THERAPY FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
EHA Learning Center, Deok-Hwan Yang, 214767
OUTPATIENT SYSTEMIC HIGH-DOSE METHOTREXATE AS CNS PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Ruben Fernandez, 214768
OUTCOME OF A 10-YEAR POPULATION-BASED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE FIRST-LINE, REFRACTORY AND RELAPSED SETTING: ‘REAL-WORLD’ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES
EHA Learning Center, Hilde van der Galien, 214769
LOW SUNLIGHT EXPOSURE AT TIME OF DLBCL DIAGNOSIS MAY BE ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY WOMEN
EHA Learning Center, Anna Elinder Camburn, 214770
THE PROGNOSTIC ROLE OF 18FDG-PET/TAC AT THE END OF FIRST LINE CHEMO-IMMUNOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: A MONOCENTRIC STUDY ON 308 PATIENTS.
EHA Learning Center, Elena Maiolo, 214771
CLINICAL CHARACTERISTICS AND OUTCOMES OF BURKITT LYMPHOMA IN A DEVELOPING COUNTRY
EHA Learning Center, Vanderson Rocha, 214772
AN INCREASED RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN CHILDREN AFTER CARDIAC TRANSPLANTATION FOR CONGENITAL HEART DISEASE
EHA Learning Center, Ugonna Offor, 214773
ASSESSMENT OF IMMUNE FUNCTION BEFORE AND AFTER TREATMENT WITH RECOMBINANT FACTOR VIII FUSED WITH FC FRAGMENTS
EHA Learning Center, Stephanie P'ng, 214774
FACTOR VIII RECOVERY TEST IN PERIOPERATIVE MANAGEMENT OF ORTHOPEDIC SURGERY IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A
EHA Learning Center, Jae Joon Han, 214775
PREDICTION OF INHIBITORS IN HAEMOPHILIA PATIENTS BY SCORE IN ONE CENTER
EHA Learning Center, Oleksandra Stasyshyn, 214776
REAL WORLD SWITCHING FROM CONVENTIONAL FVIII PRODUCTS TO RFVIIIFC IN FRANCE, GERMANY, ITALY AND THE UK
EHA Learning Center, Persefoni Kritikou, 214777
MYPKFIT HEMOPHILIA EXPERIENCE IN PEDIATRIC CASES
EHA Learning Center, Selin AYTAC, 214778
CHALLENGES OF MANAGEMENT OF REFUGEE CHILDREN WITH CONGENITAL FACTOR DEFICIENCIES
EHA Learning Center, Nihal Ozdemir, 214779
PROTEIN EXPLORER IN THE CONTEXT OF OVERLAP OF BONE MARROW FAILURE DISORDERS
EHA Learning Center, Ayodele Alaiya, 214780
NOVEL MUTATIONS IN PATIENTS WITH TELOMEROPATHIES
EHA Learning Center, Monika Haubitz, 214781
RA101495, A SUBCUTANEOUSLY-ADMINISTERED PEPTIDE INHIBITOR OF COMPLEMENT COMPONENT C5, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: PHASE 2 RESULTS
EHA Learning Center, Anita Hill, 214782
DIFFICULTIES IN DIAGNOSIS AND MANAGEMENT IN PATIENTS WITH CYCLIC NEUTROPENIA
EHA Learning Center, Cornelia Zeidler, 214783
CLINICAL AND MORPHOLOGIC PREDICTORS OF OUTCOME IN APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG
EHA Learning Center, Bruno Fattizzo, 214784
A COMPARATIVE STUDY OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY AND HAPLOIDENTICAL TRANSPLANTATION FOR YOUNG SEVERE APLASTIC ANEMIA
EHA Learning Center, Miao Chen, 214785
EFFECTIVENESS OF ECULIZUMAB IN PNH PATIENTS RECEIVING CONCOMITANT IMMUNOSUPPRESSIVE THERAPY
EHA Learning Center, Anita Hill, 214786
EFFECT OF ECULIZUMAB ON TRANSFUSION NEEDS IN PNH PATIENTS WITH AND WITHOUT TRANSFUSION HISTORY
EHA Learning Center, Alexander Röth, 214787
PROGNOSTIC SIGNIFICANCE OF RENAL DYSFUNCTION DURING THE CLINICAL COURSE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A KOREAN MULTICENTER STUDY
EHA Learning Center, Yeung-Chul Mun, 214788
COMPLEMENT ACTIVATION AND EXACERBATION OF HAEMOLYSIS SECONDARY TO RESPIRATORY VIRAL INFECTIONS IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) PATIENTS TREATED WITH ECULIZUMAB
EHA Learning Center, Ioanna Lazana, 214789
RESULTS OF COBALT, A PHASE II CLINICAL TRIAL OF COVERSIN IN PNH
EHA Learning Center, Anita Hill, 214790
THE INCIDENCE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELL CLONES IN THE NORDIC COUNTRIES
EHA Learning Center, Christian Kjellander, 214791
INTERROGATION OF HAEMATOPOIETIC BONE MARRROW PROGENITORS FOR DRIVER MUTATIONS OF CHRONIC LYMPHOCYTIC LEUKAEMIA
EHA Learning Center, David Bruce, 214792
SMG1 LOSS ENHANCES MTOR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
EHA Learning Center, Tara Roberts, 214793
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER CHEMOIMMUNOTHERAPY AND IBRUTINIB
EHA Learning Center, Luca Vincenzo Cappelli, 214794
PAPTP LEADS TO NEOPLASTIC CELL APOPTOSIS IN THE EΜ-TCL1 CHRONIC LYMPHOCYTIC LEUKEMIA MOUSE MODEL
EHA Learning Center, Filippo Severin, 214795
OVERTIME ASSESSMENT OF EPIGENETIC PROFILES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY
EHA Learning Center, MARIA TSAGIOPOULOU, 214796
JAK/SYK INHIBITION IS VITAL TO PREVENT B CELL RECEPTOR SIGNALING AND ITS REGULATION BY THE TUMOUR MICROENVIRONMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Andrew J. Steele, 214797
CLL-DERIVED EXOSOMES REPROGRAM THE PHOSPHOPRTEOMICS LANDSCAPE OF ENDOTHELIAL CELLS.
EHA Learning Center, Lian Lipshtein, 214798
CHRONIC LYMPHOCYTE LEUKEMIA CELLS SHARE A UNIQUE CIRCULAR RNA EXPRESSION PATTERN
EHA Learning Center, Oshrat Raz, 214799
T CELL CLONAL DYNAMICS ARE ASSOCIATED WITH CLINICAL RESPONSE AFTER LENALIDOMIDE CONSOLIDATION TREATMENT IN CLL
EHA Learning Center, Anastasia Hadzidimitriou, 214800
PREVALENCE AND PROGNOSTIC IMPACT OF THE IGLV3-21 G110R MUTATION IN CLL – A PATHOBIOLOGICAL REDEFINITION OF THE UNFAVORABLE CLL SUBTYPE II
EHA Learning Center, Hendrik Veelken, 214801
EVOLUTION OF GENOMIC ABNORMALITIES DURING CLL DISEASE COURSE IS ASSOCIATED WITH TELOMERE LENGTH CHANGES
EHA Learning Center, Helena Olbertova, 214802
NOTCH1, TP53, SF3B1, ATM AND BIRC3 GENE MUTATIONS ARE ASSOCIATED WITH A WORSE OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13Q LOSSES
EHA Learning Center, Ana E Rodríguez-Vicente, 214803
CHARACTERIZATION OF A NOVEL ENTITY IN CLL: SYMPTOMATIC BRONCHIAL INVOLVEMENT; A STUDY OF THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO) GROUP
EHA Learning Center, Morgane Nudel, 214804
GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE
EHA Learning Center, Michaela Spunarova, 214805
CIRCULATING SEX HORMONES AND NUCLEAR HORMONE RECEPTOR EXPRESSION ARE ASSOCIATED WITH TREATMENT-FREE SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Katrina Vanura, 214806
DESIGN AND MINION TESTING OF A NANOPORE SEQUENCING SPECIFIC GENE PANEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Francesco Albano, 214807
LOW CATALASE EXPRESSION CONFERS REDOX HYPERSENSITIVITY AND IDENTIFIES AN INDOLENT CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Maria Scupoli, 214808
STAT3 AND STAT5B MUTATIONS IN LARGE GRANULAR LYMPHOCYTES LYMPHOCYTOSIS/LEUKEMIAS: DIAGNOSTIC AND PROGNOSTIC VALUE
EHA Learning Center, Alberto Orfao, 214809
T-PLL CELLS RESEMBLE MEMORY-TYPE T-CELLS WITH ABERRANT EFFECTOR FUNCTIONS IMPLICATING A LEUKEMOGENIC COOPERATION OF TCL1A WITH TCR SIGNALING
EHA Learning Center, Sebastian Oberbeck, 214810
INTEGRATED GENETIC PROFILES OF T-PLL IMPLICATE A TCL1/ATM-CENTERED MODEL OF ABERRANT DNA DAMAGE RESPONSES
EHA Learning Center, Alexandra Schrader, 214811
CG’806, A NON-COVALENT PAN-FLT3/PAN-BTK INHIBITOR, EXHIBITS UNIQUE BINDING TO WILD TYPE AND C481S MUTANT BTK AND GREATER POTENCY THAN IBRUTINIB AGAINST MALIGNANT B CELLS
EHA Learning Center, Hongying Zhang, 214812
DISTINCT IMMUNE SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER’S SYNDROME
EHA Learning Center, Yucai Wang, 214813
DURABILITY OF RESPONSE TO VENETOCLAX (VEN) IN PATIENTS WITH CLL RELAPSED/REFRACTORY TO IBRUTINIB AND/OR IDELALISIB
EHA Learning Center, John C. Byrd, 214814
SALVAGE USE OF IBRUTINIB AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA OR MANTLE CELL LYMPHOMA : A STUDY ON BEHALF OF THE SFGM-TC AND THE EBMT
EHA Learning Center, Mauricette Michallet, 214815
MANAGEMENT, ADVERSE EVENTS, AND OUTCOMES OF 282 CLL PATIENTS (PTS) TREATED WITH VENETOCLAX (VEN) IN THE REAL WORLD
EHA Learning Center, Chadi Nabhan, 214816
IBRUTINIB FOR FIRST-LINE TREATMENT OF OLDER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): A 4-YEAR EXPERIENCE FROM THE RESONATE-2 STUDY
EHA Learning Center, Jan A Burger, 214817
IMPACT OF TP53-MUTATED CLONE SIZE ON OUTCOME OF RELAPSED/REFRACTORY (R/R) CLL PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB WITHIN THE PHASE 3 MURANO STUDY
EHA Learning Center, Arnon Kater, 214818
SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL
EHA Learning Center, Carsten Niemann, 214819
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: UPDATED RESULTS FROM THE NCRI RIALTO TRIAL.
EHA Learning Center, Andrew Pettitt, 214820
OBINUTUZUMAB PRE-INDUCTION ABROGATES HIGH TUMOR LYSIS RISK OF VENETOCLAX IN TREATMENT NAÏVE FCR-UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PLANNED INTERIM ANALYSIS.
EHA Learning Center, Mark David Levin, 214821

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings